A phase 1/2a study to test the safety and immunogenicity of a p16INK4apeptide vaccine in patients with advanced human papillomavirus-associated cancers

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

(2015) Cornelia L Trimble et al.   LANCET

p16INK4a/Ki-67 co-expression specifically identifies transformed cells in the head and neck region

(2014) Elena-Sophie Prigge et al.   INTERNATIONAL JOURNAL OF CANCER

The clinical impact of using p16INK4aimmunochemistry in cervical histopathology and cytology: An update of recent developments

(2014) Christine Bergeron et al.   INTERNATIONAL JOURNAL OF CANCER

Depletion of the cdk Inhibitor p16INK4a Differentially Affects Proliferation of Established Cervical Carcinoma Cells

(2014) A. Pauck et al.   JOURNAL OF VIROLOGY

The role of senescent cells in ageing

(2014) Jan M. van Deursen   NATURE

Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer

(2014) Julia Scheiermann et al.   VACCINE

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

(2013) Mariette I E van Poelgeest et al.   Journal of Translational Medicine

Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines

(2013) M. E. McLaughlin-Drubin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer

(2012) O. J. Finn   ANNALS OF ONCOLOGY

A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions

(2012) Peggy J. de Vos van Steenwijk et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Biomarkers for cervical cancer screening: the role of p16INK4ato highlight transforming HPV infections

(2012) Magnus von Knebel Doeberitz et al.   Expert Review of Proteomics

Global Burden of Human Papillomavirus and Related Diseases

(2012) David Forman et al.   VACCINE

Evaluation of cervical cone biopsies for coexpression of p16INK4a and Ki-67 in epithelial cells

(2011) Miriam Reuschenbach et al.   INTERNATIONAL JOURNAL OF CANCER

Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming

(2011) Margaret E. McLaughlin-Drubin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Host Factors in HPV-related Carcinogenesis: Cellular Mechanisms Controlling HPV Infections

(2009) Magnus von Knebel Doeberitz et al.   ARCHIVES OF MEDICAL RESEARCH

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

(2009) Gemma G. Kenter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Papillomaviruses in the causation of human cancers — a brief historical account

(2009) Harald zur Hausen   VIROLOGY

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

(2008) G. G. Kenter et al.   CLINICAL CANCER RESEARCH

Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers

(2008) Miriam Reuschenbach et al.   INTERNATIONAL JOURNAL OF CANCER